First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals

Authors
Category Primary study
JournalBlood
Year 2015
This article has no abstract
Epistemonikos ID: d368b92ec5637fc39819883a0105064cd09833b7
First added on: Feb 19, 2025